- Trial phase
- Approved (accelerated approval)
- Time to market
- Already approved and commercially available in the US (since April 2023) and EU (since May 2024), plus 42 other countries.
- Why 3/10
- QALSODY is already FDA-approved (accelerated approval, April 2023) and commercially launched. The next hard catalyst is the ATLAS Phase 3 confirmatory trial readout, but its estimated primary completion is August 2027, more than 12 months away. No PDUFA or pivotal readout is scheduled in the next year. QALSODY is a small part of Biogen's large, diversified pipeline (~$10B total revenue), so even a major QALSODY-specific event would not be a make-or-break binary for the stock.
The next hard catalyst for QALSODY is the ATLAS Phase 3 confirmatory trial readout, but its estimated primary completion is August 2027, more than 12 months away. With no imminent PDUFA or pivotal readout, QALSODY is unlikely to drive a major standalone move in BIIB shares in the near term. Watch for quarterly sales growth trajectory and any updates on the ATLAS enrollment or potential interim analysis.
Price Chart
Executive Summary
QALSODY (tofersen) is an FDA-approved antisense oligonucleotide therapy from Biogen (BIIB) that targets the genetic cause of SOD1-ALS, an ultra-rare neurodegenerative disease affecting roughly 2% of ALS patients. It received accelerated FDA approval in April 2023 based on biomarker data (reduction in neurofilament light chain), followed by European approval in May 2024. The drug is now approved in 44 countries and generated approximately $33M in global revenue in Q1 2026. While long-term data published in JAMA Neurology (December 2025) showed that early treatment slows functional decline, the drug's commercial impact on Biogen is modest given the tiny patient population. The key upcoming catalyst is the ATLAS Phase 3 confirmatory trial in presymptomatic SOD1 carriers, but its estimated primary completion is August 2027, leaving no imminent binary event for this drug.
How It Works
QALSODY is an antisense oligonucleotide (a short, lab-made piece of genetic material) designed to bind to the messenger RNA that carries instructions for making the SOD1 protein. By binding to this RNA, it reduces production of the SOD1 protein, which in its mutated form is toxic to nerve cells and causes ALS. The drug is administered via lumbar puncture (intrathecal injection into the spinal fluid) every few weeks.
Trial Status
QALSODY is FDA-approved under accelerated approval based on the Phase 3 VALOR trial and its open-label extension. The confirmatory Phase 3 ATLAS trial (NCT04856982) in presymptomatic SOD1 mutation carriers is active but not recruiting, with an estimated primary completion date of August 2027 and final completion in April 2028. A Phase 2 trial in non-SOD1 ALS began enrollment in December 2025. Long-term VALOR OLE results were published in JAMA Neurology in December 2025, showing that early treatment with tofersen slows functional decline and reduces neurofilament light levels over 2+ years.
The Two-Sided Case
Upcoming Catalysts
- ATLAS Phase 3 confirmatory trial primary completion (estimated August 2027) - could support conversion from accelerated to full FDA approval
- Phase 2 trial in non-SOD1 ALS (started December 2025) - if positive, could dramatically expand addressable market
- Quarterly sales growth trajectory as global reimbursement expands across 44 approved countries
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOGEN INC. 8-K BIIB ·Originating report